Association of post-diagnosis cardiorespiratory fitness with cause-specific mortality in cancer.
Cancer
Cancer mortality
Cardiac rehab
Cardio-oncology
Cardiorespiratory fitness
Cardiovascular mortality
Cause-specific mortality
Exercise
Mortality
Journal
European heart journal. Quality of care & clinical outcomes
ISSN: 2058-1742
Titre abrégé: Eur Heart J Qual Care Clin Outcomes
Pays: England
ID NLM: 101677796
Informations de publication
Date de publication:
01 10 2020
01 10 2020
Historique:
received:
11
09
2019
accepted:
10
03
2020
pubmed:
14
3
2020
medline:
6
7
2021
entrez:
14
3
2020
Statut:
ppublish
Résumé
The prognostic importance of post-diagnosis assessment of cardiorespiratory fitness (CRF) in cancer patients is not well established. We sought to examine the association between CRF and mortality in cancer patients. This was a single-centre cohort analysis of 1632 patients (58% male; 64 ± 12 years) with adult-onset cancer who were clinically referred for exercise treadmill testing a median of 7 [interquartile range (IQR): 3-12] years after primary diagnosis. Cardiorespiratory fitness was defined as peak metabolic equivalents (METs) achieved during standard Bruce protocol and categorized by tertiles. The association between CRF and all-cause and cause-specific mortality was assessed using multivariable Cox proportional hazard models adjusting for important covariates. Median follow-up was 4.6 (IQR: 2.6-7.0) years; a total of 411 deaths (229, 50, and 132 all-cause, cardiovascular (CV), and cancer related, respectively) occurred during this period. Compared with low CRF (range: 1.9-7.6 METs), the adjusted hazard ratio (HR) for all-cause mortality was 0.38 [95% confidence interval (CI): 0.28-0.52] for intermediate CRF (range: 7.7-10.6 METs) and 0.17 (95% CI: 0.11-0.27) for high CRF (range: 10.7-22.0 METs). The corresponding HRs were 0.40 (95% CI: 0.19-0.86) and 0.41 (95% CI: 0.16-1.05) for CV mortality and 0.40 (95% CI: 0.26-0.60) and 0.16 (95% CI: 0.09-0.28) for cancer mortality, respectively. The adjusted risk of all-cause, CV, and cancer mortality decreased by 26%, 14%, and 25%, respectively with each one MET increment in CRF. Cardiorespiratory fitness is a strong, independent predictor of all-cause, CV, and cancer mortality, even after adjustment for important clinical covariates in patients with certain cancers.
Identifiants
pubmed: 32167560
pii: 5804986
doi: 10.1093/ehjqcco/qcaa015
pmc: PMC9989596
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
315-322Subventions
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Informations de copyright
Published on behalf of the European Society of Cardiology. All rights reserved. © The Author(s) 2020. For permissions, please email: journals.permissions@oup.com.
Références
Lung Cancer. 2012 May;76(2):248-52
pubmed: 22112290
Bone Marrow Transplant. 2014 Oct;49(10):1330-6
pubmed: 25068429
J Am Coll Cardiol. 2003 Dec 17;42(12):2139-43
pubmed: 14680741
J Am Soc Echocardiogr. 2013 Sep;26(9):1013-32
pubmed: 23998694
J Clin Oncol. 2003 May 1;21(9):1819-24
pubmed: 12721259
J Heart Lung Transplant. 1995 Sep-Oct;14(5):981-9
pubmed: 8800737
JAMA Oncol. 2015 May;1(2):231-7
pubmed: 26181028
Bone Marrow Transplant. 2013 Oct;48(10):1342-9
pubmed: 23584437
J Gerontol A Biol Sci Med Sci. 2001 Mar;56(3):M146-56
pubmed: 11253156
Cancer Med. 2019 Jan;8(1):447-454
pubmed: 30578624
Cancer. 2005 Nov 1;104(9):1998-2005
pubmed: 16206252
J Clin Oncol. 2017 Mar 10;35(8):893-911
pubmed: 27918725
N Engl J Med. 2002 Mar 14;346(11):793-801
pubmed: 11893790
Eur Heart J. 2016 Sep 21;37(36):2768-2801
pubmed: 27567406
JAMA Netw Open. 2018 Oct 5;1(6):e183605
pubmed: 30646252
Blood. 2005 Oct 15;106(8):2912-9
pubmed: 15994282
Acta Oncol. 2016 Dec;55(12):1386-1391
pubmed: 27718777
Circulation. 2017 Apr 18;135(16):e894-e918
pubmed: 28336790
J Am Coll Cardiol. 2015 Feb 17;65(6):573-83
pubmed: 25677317
JAMA Oncol. 2018 Oct 1;4(10):1352-1358
pubmed: 29862412
J Clin Oncol. 2012 Jul 10;30(20):2530-7
pubmed: 22614980
J Clin Oncol. 1995 Jun;13(6):1453-8
pubmed: 7751892
Lancet Oncol. 2009 Jun;10(6):598-605
pubmed: 19482248
Circulation. 2002 Aug 6;106(6):666-71
pubmed: 12163425
Circ J. 2008 Apr;72(4):575-81
pubmed: 18362428
Am Heart J. 1999 Oct;138(4 Pt 1):740-5
pubmed: 10502221
Chest. 2007 Dec;132(6):1778-85
pubmed: 17925409
Circulation. 2013 Aug 20;128(8):873-934
pubmed: 23877260
Br J Cancer. 1997;75(5):698-702
pubmed: 9043027
Circulation. 2003 Sep 30;108(13):1554-9
pubmed: 12975254
Ann Palliat Med. 2016 Apr;5(2):83-92
pubmed: 27121736
Circulation. 1998 Dec 22-29;98(25):2836-41
pubmed: 9860784
J Clin Oncol. 1996 Aug;14(8):2197-205
pubmed: 8708708
Br J Cancer. 2016 Jul 12;115(2):178-87
pubmed: 27351215
J Clin Oncol. 2018 Aug 1;36(22):2297-2305
pubmed: 29894274
Cancer. 2010 Oct 15;116(20):4825-32
pubmed: 20597134
Clin Cancer Res. 2016 Oct 1;22(19):4766-4775
pubmed: 27407093
Circulation. 1997 Jul 1;96(1):345-54
pubmed: 9236456
Circulation. 2019 May 21;139(21):e997-e1012
pubmed: 30955352
J Clin Oncol. 2000 Feb;18(3):562-73
pubmed: 10653871
Ann Oncol. 2001 Jan;12(1):81-7
pubmed: 11249054
Angiology. 1973 Dec;24(11):691-702
pubmed: 4543577